BTIG Research Reiterates “Buy” Rating for Stoke Therapeutics (NASDAQ:STOK)

Stoke Therapeutics (NASDAQ:STOK)‘s stock had its “buy” rating reaffirmed by equities researchers at BTIG Research in a report released on Thursday,Benzinga reports. They presently have a $39.00 target price on the stock. BTIG Research’s price target points to a potential upside of 16.38% from the company’s current price.

A number of other analysts also recently commented on STOK. Wedbush upped their price objective on Stoke Therapeutics from $36.00 to $38.00 and gave the stock an “outperform” rating in a report on Tuesday. UBS Group set a $50.00 target price on shares of Stoke Therapeutics in a research report on Monday, December 15th. Wolfe Research assumed coverage on Stoke Therapeutics in a research note on Monday, February 23rd. They issued an “outperform” rating and a $40.00 price target on the stock. Canaccord Genuity Group increased their price objective on shares of Stoke Therapeutics from $28.00 to $36.00 and gave the company a “buy” rating in a research note on Monday, January 5th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Stoke Therapeutics in a research report on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, Stoke Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $41.83.

Stoke Therapeutics Stock Performance

Stoke Therapeutics stock opened at $33.51 on Thursday. The company has a market capitalization of $1.98 billion, a price-to-earnings ratio of 50.01 and a beta of 1.07. The stock has a fifty day moving average of $32.61 and a two-hundred day moving average of $30.02. Stoke Therapeutics has a fifty-two week low of $5.35 and a fifty-two week high of $40.22.

Insider Activity

In other news, insider Barry Ticho sold 6,686 shares of Stoke Therapeutics stock in a transaction dated Wednesday, March 18th. The stock was sold at an average price of $31.34, for a total value of $209,539.24. Following the transaction, the insider directly owned 40,798 shares in the company, valued at approximately $1,278,609.32. The trade was a 14.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, General Counsel Jonathan Allan sold 4,628 shares of the business’s stock in a transaction on Wednesday, March 18th. The stock was sold at an average price of $31.34, for a total transaction of $145,041.52. Following the transaction, the general counsel directly owned 28,836 shares in the company, valued at $903,720.24. This trade represents a 13.83% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 69,699 shares of company stock valued at $2,526,714. 9.50% of the stock is currently owned by company insiders.

Institutional Trading of Stoke Therapeutics

A number of large investors have recently bought and sold shares of the stock. Kestra Advisory Services LLC bought a new stake in Stoke Therapeutics during the 4th quarter worth approximately $26,000. Harbour Investments Inc. raised its stake in shares of Stoke Therapeutics by 312.9% during the fourth quarter. Harbour Investments Inc. now owns 1,185 shares of the company’s stock worth $38,000 after buying an additional 898 shares during the last quarter. Generali Investments Management Co LLC acquired a new position in Stoke Therapeutics in the third quarter valued at approximately $41,000. BNP Paribas Financial Markets lifted its holdings in Stoke Therapeutics by 66.2% in the second quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock valued at $48,000 after buying an additional 1,668 shares during the period. Finally, Tower Research Capital LLC TRC boosted its stake in Stoke Therapeutics by 461.0% in the second quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company’s stock valued at $50,000 after acquiring an additional 3,591 shares during the last quarter.

More Stoke Therapeutics News

Here are the key news stories impacting Stoke Therapeutics this week:

• Positive Sentiment: Canaccord raised its price target sharply to $60 and assigned a Buy, giving STOK a meaningful upside projection versus recent levels — a clear catalyst for buying interest. Canaccord raises STOK price target to $60 (Benzinga)
• Positive Sentiment: Other analysts reiterated/raised Buy views and targets (BTIG reaffirmed Buy with a $39 target; Wedbush pushed its target to $38; Needham published a bullish outlook), adding breadth to the bullish narrative and likely attracting momentum and institutional buyers. BTIG reaffirmation (Benzinga) Wedbush boosts price target to $38 (AmericanBankingNews) Needham bullish outlook (AmericanBankingNews)
• Positive Sentiment: Coverage of Stoke’s STK‑001 program emphasizes potential beyond seizure reduction (aiming to restore developmental loss in Dravet syndrome), supporting longer‑term upside expectations if clinical data meet endpoints. FierceBiotech: Stoke aims to restore developmental loss in Dravet syndrome
• Neutral Sentiment: Analysis pieces reviewed a recent sharp pullback and what triggered it—useful context for traders but not a new company catalyst. Kalkine: What triggered the sudden drop?
• Neutral Sentiment: Technical/volume note — today’s volume is well above average and the stock is trading above both its 50‑ and 200‑day SMAs, indicating higher investor interest; this can amplify moves in either direction.
• Negative Sentiment: Significant insider selling: multiple executives (including the CFO, general counsel and senior insiders such as Barry Ticho) disclosed sizable sales across March 17–19, which can weigh on sentiment and prompt investor caution despite analyst optimism. Representative SEC filings: SEC Form 4 (Jonathan Allan) SEC Form 4 (Barry Ticho)

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.